Form 4: Macrogenics Director Karen Ferrante Trades Shares

Macrogenics Inc. reports director Karen Ferrante's transactions involving restricted stock units and stock options.

Summary

• Karen Jean Ferrante, a Director at Macrogenics Inc. (MGNX), reported several transactions on May 18-19, 2026.
• She acquired 3,750 shares of common stock upon the vesting of restricted stock units (RSUs) on May 18, 2026.
• An additional 3,750 RSUs were acquired on May 19, 2026, which are set to vest one year after the grant date or the day prior to the next annual meeting.
• Ferrante also acquired a stock option to buy 22,000 shares of common stock at an exercise price of $4.52, which vests and becomes exercisable in monthly increments starting one month from the grant date, with an expiration date of May 19, 2036.
• Following these transactions, Ferrante beneficially owns 14,750 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports routine insider transactions rather than company performance or strategic shifts.

Positives

• Director Karen Ferrante acquired 3,750 shares of common stock through RSU vesting, indicating continued equity ownership.
• An additional 3,750 RSUs were granted, suggesting ongoing incentive alignment with the company's performance.
• A stock option for 22,000 shares was acquired, providing potential for future equity gains for the director.

Negatives

• The filing does not explicitly detail any negative financial outcomes or operational setbacks.

Risks

• The vesting of RSUs and exercise of stock options are subject to continued employment and company performance, which could be impacted by market conditions or operational challenges.
• The value of the acquired stock options is contingent on the future stock price of Macrogenics Inc.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance. It solely reports on insider transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently reflect company performance. Such filings are crucial for monitoring executive confidence and potential shifts in beneficial ownership within the biotechnology sector.

Stakeholder Impact

• Shareholders: The transactions may provide insight into a director's confidence in the company's future stock performance, but do not directly impact current share value.
• Employees: The granting of RSUs and stock options to management can be seen as a retention and incentive tool, aligning executive interests with long-term company success.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• The acquired stock option will vest and become exercisable in monthly increments starting one month from the grant date.
• The newly acquired RSUs will vest one year after the grant date or the day prior to the next annual meeting, if earlier.

Key Dates

Keywords

Macrogenics Inc., MGNX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Karen Jean Ferrante, Director, Beneficial Ownership, SEC Filing